Paratek Pharmaceuticals (FRA:N4CN) Construction In Progress : €0.0 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Paratek Pharmaceuticals Construction In Progress?

Paratek Pharmaceuticals's quarterly construction in progress declined from Dec. 2022 (€0.2 Mil) to Mar. 2023 (€0.0 Mil) but then stayed the same from Mar. 2023 (€0.0 Mil) to Jun. 2023 (€0.0 Mil).

Paratek Pharmaceuticals's annual construction in progress increased from Dec. 2020 (€0.2 Mil) to Dec. 2021 (€0.2 Mil) and increased from Dec. 2021 (€0.2 Mil) to Dec. 2022 (€0.2 Mil).

Paratek Pharmaceuticals Construction In Progress Historical Data

The historical data trend for Paratek Pharmaceuticals's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Construction In Progress Chart

Paratek Pharmaceuticals Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Construction In Progress

Get a 7-Day Free Trial

0.16

0.17

0.21

Paratek Pharmaceuticals Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Construction In Progress	Get a 7-Day Free Trial															-	-	0.21	-	-

Paratek Pharmaceuticals Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Paratek Pharmaceuticals (FRA:N4CN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (FRA:N4CN) » Definitions » Construction In Progress

Comparable Companies

Traded in Other Exchanges

N/A

Address

75 Park Plaza, 4th Floor, Boston, MA, USA, 02116

Website

https://www.paratekpharma.com

Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.

Paratek Pharmaceuticals (FRA:N4CN) Headlines

No Headlines